Abstract:As a potential preclinical stage of Alzheimer's dementia, subjective cognitive decline (SCD) reveals a higher risk of future cognitive decline and conversion to dementia. However, it has not been clear whether SCD status increases the clinical progression of older adults in the context of amyloid deposition, cerebrovascular disease (CeVD), and psychiatric symptoms. We identified 99 normal controls (NC), 15 SCD individuals who developed mild cognitive impairment in the next 2 years (P-SCD), and 54 SCD individuals who did not (S-SCD) from ADNI database with both baseline and 2-year follow-up data. Total white matter hyperintensity (WMH), WMH in deep (DWMH) and periventricular (PWMH) regions, and voxel-wise grey matter volumes were compared among groups. Furthermore, using structural equation modelling method, we constructed path models to explore SCD-related brain changes longitudinally and to determine whether baseline SCD status, age, and depressive symptoms affect participants' clinical outcomes. Both SCD groups showed higher baseline amyloid PET SUVR, baseline PWMH volumes, and larger increase of PWMH volumes over time than NC. In contrast, only P-SCD had higher baseline DWMH volumes and larger increase of DWMH volumes over time than NC. No longitudinal differences in grey matter volume and amyloid was observed among NC, S-SCD, and P-SCD. Our path models demonstrated that SCD status contributed to future WMH progression. Further, baseline SCD status increases the risk of future cognitive decline, mediated by PWMH; baseline depressive symptoms directly contribute to clinical outcomes. In conclusion, both S-SCD and P-SCD exhibited more severe CeVD than NC. The CeVD burden increase was more pronounced in P-SCD. In contrast with the direct association of depressive symptoms with dementia severity progression, the effects of SCD status on future cognitive decline may manifest via CeVD pathologies. Our work highlights the importance of multi-modal longitudinal designs in understanding the SCD trajectory heterogeneity, paving the way for stratification and early intervention in the preclinical stage. PRACTITIONER POINTS: Both S-SCD and P-SCD exhibited more severe CeVD at baseline and a larger increase of CeVD burden compared to NC, while the burden was more pronounced in P-SCD. Baseline SCD status increases the risk of future PWMH and DWMH volume accumulation, mediated by baseline PWMH and DWMH volumes, respectively. Baseline SCD status increases the risk of future cognitive decline, mediated by baseline PWMH, while baseline depression status directly contributes to clinical outcome.

Prognostic prediction of subjective cognitive decline in major depressive disorder based on immune biomarkers: a prospective observational study

Linking peripheral IL-6, IL-1 and hypocretin-1 with cognitive impairment from major depression

Sociodemographic Factors Predict Incident Mild Cognitive Impairment: A Brief Review and Empirical Study.

Association of Subjective Cognitive Decline with Risk of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Prospective Longitudinal Studies

Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline

Synergistic Effect of Cardiometabolic Multimorbidity and Depression on Longitudinal Cognitive Decline: Results from Two Longitudinal Asian Elderly Cohorts

Predictors of cognitive deterioration in subjective cognitive decline: evidence from longitudinal studies and implications for SCD-plus criteria

Neurocognitive Characteristics of Subjective Cognitive Decline and Its Association with Objective Cognition, Negative Emotion, and Sleep Quality in Chinese Elderly

Neuropsychiatric symptoms as prognostic makers for the elderly with mild cognitive impairment: a meta-analysis

Changes in Multiparametric Magnetic Resonance Imaging and Plasma Amyloid-Beta Protein in Subjective Cognitive Decline

Longitudinal assessment of plasma biomarkers for early detection of cognitive changes in subjective cognitive decline

Prevalence and risk factors of subjective cognitive decline in older adults in Baotou, China: a cross-sectional study

Exploring the links among peripheral immunity, biomarkers, cognition, and neuroimaging in Alzheimer's disease

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease

Analysis of Immune Dysfunction and Predictors of Poor Prognosis in Patients with Alzheimer's Disease

Prevalence and risk factors for subjective cognitive decline and the correlation with objective cognition among community-dwelling older adults in China: Results from the Hubei memory and aging cohort study

The research progress in clinical characteristics and imaging of subjective cognitive decline

Biomarkers of Alzheimer’s disease and cerebrovascular disease in relation to depressive symptomatology in individuals with subjective cognitive decline

Genes associated with cellular senescence as diagnostic markers of major depressive disorder and their correlations with immune infiltration

Brain structure, amyloid, and behavioral features for predicting clinical progression in subjective cognitive decline

Prediction of clinical progression of subjective cognitive decline through alterations in morphology and structural covariance networks